E112: Is Davos a grift? Plus: globalist mishaps, debt ceilings, TikTok's endgame & more
2023-01-20 spoken.md · speaker-labeled ▶ watch ← E111 all episodes E113 →
Every number here is replayed from score_events — the same ledger the pool ranks on. Decay is what the 110 ideas nobody mentioned gave up this week; it applies only when an episode is processed.
Tier crossings
conviction thresholds crossed by this episode — 65 / 45 / 15 · ideas born here show where they landed. why 65 isn't always green
Kill dates that landed since E111
0 hit · 0 partial · 1 miss — windows that closed after 2023-01-13 and up to 2023-01-20, auto-scored against price data and never hand-set. verdict · R · α
| idea | verdict | R | α | closed |
|---|---|---|---|---|
| 📈 EBV-causes-MS proof turns Epstein-Barr into a funded therapeutic target | MISS | -73.9% | -62.6 | 2023-01-15 |
Who moved the board
each voice's force on conviction this episode — supports and opposes, weighted exactly as the replay applied them · share = % of this episode's movement
What got argued (8 ideas)
ordered by how hard each idea moved · quotes are verbatim from the transcript, timestamps deep-link into the episode
All the political anger aimed at Facebook and Google gets redirected at ByteDance because picking a fight with a Chinese company is easy and popular, and US big tech will happily point the finger over there. Chamath's read: TikTok's enterprise value is badly impaired (a $70-80B markdown, 35-40% off the $320B mark), the next shoe is advertisers pulling back under political pressure, and cap-table holders should sell into secondary. ByteDance is private, so the tradeable side is the US ad platforms that absorb the share and the ad dollars.
So I don't think this is going to end well for TikTok. And I think the goal, if I were any of these people on the cap table, would be to sell it in secondary to somebody else and get out. I think the next big shoe to drop is going to be advertisers who come under a lot of pressure.
Chamath's call on the 2023 budget showdown: debt-to-GDP has no magic failure threshold, so the fiscal hawks lose. Republicans hem and haw and then capitulate, the ceiling gets raised, and Washington keeps funding the onshoring/deglobalization build-out because that spending lands in red states that would otherwise wither. No default, no forced austerity — a non-event for risk assets.
Chamath's disclosed positioning: he is putting real money into places that control natural resources nobody has properly mapped — India above all, where geological survey coverage is naive relative to what's there, plus Indonesia, Australia and parts of Africa. Governments in those places are sophisticated enough to price full employment into their cost of capital and accept a longer payback to keep processing at home rather than shipping inputs to China, so the raw-material rents move out of China's orbit even before energy costs are considered.
Friedberg's repeated claim, framed as playing out over the next couple of years: China is building 450 nuclear power plants, driving industrial power below 4-5 cents/kWh and electrifying its factories, so the unit of production stops being human labor and becomes a unit of electricity. Whoever has the cheapest electricity has a structural manufacturing cost advantage, which undercuts the West's onshoring economics. Chamath disputes it — cheap energy doesn't help if you don't control the material inputs.
My point was that in China, and I've made this point many times, but I just think it's a really important one that will play out over the next couple of years. They're building 450 nuclear power plants, they're going to get the cost of industrial power below five cents or four cents a kilowatt hour, and they're electrifying all their factories.
Chamath's contrarian read off the BioNTech/InstaDeep deal: exit values for ML-in-pharma companies have gone DOWN even as the technology got far better (Flatiron Health sold for $1.9B in 2018 and is still the high-water mark), because none of it has been shown to improve the design-space guess that actually drives pharma's batting average. Every pharma gets the capability as an adjunct and pays less for it, so the listed AI-drug-discovery cohort is overvalued; the only model that captures real value is giving the tools away for a back-end royalty (Royalty Pharma is his template).
And so what's really happened is the value of acquisition in M&A has gone down, even as the technology capability has gone way, way up. And why is that? It's because this stuff has yet to be proven to actually meaningfully improve the hit rate for these drug companies.
Episode digest
written during extraction and stored in data/extractions/ep112.json — the auditable source of truth, including everything market-adjacent that did not earn a capture
Friedberg guest-moderated (Jason lost his voice and sat in the guest chair) and the fiscal thread was the episode: Friedberg restated the debt burden as his number one concern on Earth, Jason publicly converted to austerity and backed the Republicans in the debt-ceiling fight, and Sacks cited 350% global debt-to-GDP — three voices reinforcing the E024 fiscal-crunch idea, while Chamath took the other side hard, calling debt-to-GDP an intellectual red herring with no magic failure number and predicting Congress capitulates, raises the ceiling and keeps funding the onshoring build (new idea). Under the Davos grift-commentary, Chamath and Friedberg both reaffirmed deglobalization as structurally higher prices (Chamath again rejecting Friedberg's lower-growth rider), Sacks pinned China's rise on MFN and a coming security competition, and Chamath disclosed he is deploying real money into under-surveyed resource geographies, India above all. TikTok drew the sharpest new call: Chamath says ByteDance equity is impaired 35-40% off its $320B mark, advertisers are the next shoe and holders should dump into secondary — Sacks and Jason agreed, Friedberg dissented that you cannot switch off an app 100 million people use two hours a day. On AI, Chamath argued ML-in-pharma exit values are falling because nothing has improved pharma hit rates (Friedberg disagreed via the in-silico funnel argument) and Jason called ChatGPT a parlor trick only slightly faster than a Google search. DIARIZATION: there is no David Friedberg label in this file — his 106 turns are labelled 'Nick Friedberg', the producer's first name welded onto Friedberg's cluster (same shape as 'Erik Friedberg' in E093/E095). Content confirms Friedberg throughout (Google 2004, Monsanto, ag/pharma ML, the Yamanaka epigenetics science-corner sign-off naming his three co-hosts, addressed as 'Friedberg' by name), so all his mentions are canonicalized to Friedberg; the other three labels content-check clean.